CheckMate 9LA — Nivolumab Plus Ipilimumab With Two Cycles of Chemotherapy Versus Chemotherapy Alone as First-Line Treatment for Metastatic NSCLC

Phase 3 · 2021 · Non-Small Cell Lung Cancer

Design

Randomized nivolumab plus ipilimumab with only two early cycles of chemotherapy vs four cycles of chemotherapy alone.

Population

Untreated stage IV or recurrent NSCLC without EGFR/ALK alterations, any PD-L1 and any histology.

Primary Endpoint

overall survival (OS)

Key Result

OS 15.8 vs 11.0 mo (HR 0.72); durable benefit maintained at long-term follow-up across PD-L1 and histology subgroups.

Guideline Impact

NCCN-recommended first-line nivolumab + ipilimumab + 2 cycles chemotherapy for metastatic NSCLC